INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 171 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $24,000 | +500.0% | 190 | +280.0% | 0.00% | – |
Q2 2019 | $4,000 | -33.3% | 50 | 0.0% | 0.00% | – |
Q1 2019 | $6,000 | +20.0% | 50 | 0.0% | 0.00% | – |
Q4 2018 | $5,000 | -16.7% | 50 | 0.0% | 0.00% | – |
Q3 2018 | $6,000 | +50.0% | 50 | 0.0% | 0.00% | – |
Q2 2018 | $4,000 | +33.3% | 50 | 0.0% | 0.00% | – |
Q1 2018 | $3,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q4 2017 | $3,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q3 2017 | $3,000 | -50.0% | 50 | 0.0% | 0.00% | – |
Q2 2017 | $6,000 | 0.0% | 50 | 0.0% | 0.00% | – |
Q1 2017 | $6,000 | +20.0% | 50 | 0.0% | 0.00% | – |
Q4 2016 | $5,000 | -37.5% | 50 | 0.0% | 0.00% | – |
Q3 2016 | $8,000 | +14.3% | 50 | 0.0% | 0.00% | – |
Q2 2016 | $7,000 | -50.0% | 50 | 0.0% | 0.00% | – |
Q1 2016 | $14,000 | +100.0% | 50 | 0.0% | 0.00% | – |
Q4 2015 | $7,000 | -12.5% | 50 | 0.0% | 0.00% | – |
Q3 2015 | $8,000 | -33.3% | 50 | 0.0% | 0.00% | – |
Q2 2015 | $12,000 | -14.3% | 50 | 0.0% | 0.00% | – |
Q1 2015 | $14,000 | +75.0% | 50 | 0.0% | 0.00% | – |
Q4 2014 | $8,000 | – | 50 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 234,375 | $23,623,000 | 22.67% |
Boxer Capital, LLC | 600,000 | $60,474,000 | 7.47% |
DLD Asset Management, LP | 834,600 | $84,136,000 | 5.77% |
GREAT POINT PARTNERS LLC | 200,000 | $20,158,000 | 2.55% |
BB BIOTECH AG | 575,719 | $58,027,000 | 1.86% |
Elk Creek Partners, LLC | 207,657 | $20,930,000 | 1.74% |
ALTRINSIC GLOBAL ADVISORS LLC | 277,944 | $28,014,000 | 1.34% |
Sarissa Capital Management LP | 54,000 | $5,442,000 | 1.21% |
QCM Cayman, Ltd. | 2,181 | $220,000 | 0.90% |
Opus Point Partners Management, LLC | 3,534 | $356,000 | 0.78% |